Concepedia

Michael Rael

MR

Statistics

Publications

2

Citations

46

H-Index

2

Active since

2019

Affiliations

Bristol-Myers Squibb (United States)(Current)

Cleveland Clinic

Beth Israel Deaconess Medical Center

Ithaka Harbors

Michael Rael is an author at Bristol-Myers Squibb (United States) specializing in immunotherapy, medicine, and oncology.

Publications per year

2019–2019

2

Publications

2

Comparative Efficacy of Combination Immunotherapy And Targeted Therapy in the Treatment of <i>BRAF</i> -mutant Advanced Melanoma: A Matching-Adjusted Indirect Comparison

Michael B. Atkins, Ahmad A. Tarhini, Michael Rael et al. · Immunotherapy · 2019 · 35 citations · Full text

, , +17

Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.

David F. McDermott, Brian I. Rini, Robert J. Motzer et al. · Journal of Clinical Oncology · 2019 · 11 citations

, , +13

1–2 of 2